Status:
COMPLETED
Living With Sickle Cell Disease in the COVID-19 Pandemic
Lead Sponsor:
National Human Genome Research Institute (NHGRI)
Conditions:
Isolation
Anxiety
Eligibility:
All Genders
18+ years
Brief Summary
Background: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their fun...
Detailed Description
Study Description: Longitudinal online survey of adults living with sickle cell disease (SCD) in the United States. The objective of the study is to examine the extent and impact of life changes indu...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Adults, aged 18 years or older, of any race, sex, gender, ethnicity, and/or nationality
- Sickle Cell Disease, any genotype
- Current Resident of the United States
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Minors less than 18 years of age
- Adults with Sickle Cell Trait, Beta Thalassemia, Alpha Thalassemia or any blood disorder other than Sickle Cell Disorder
- Adults who lack access to the Internet
- Live outside the United States (unless they are from the INSIGHTS Study)
Exclusion
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 18 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04417673
Start Date
June 15 2020
End Date
May 18 2022
Last Update
April 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, United States, 20892